New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
07:23 EDTPCRXPacira Pharmaceuticals upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Pacira Pharmaceuticals to Overweight citing the FDA approval of new manufacturing capacity for Exparel. Piper believes Pacira is now able to meet the continued growth in Exparel demand and raised its price target for shares to $84 from $75.
News For PCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2016
15:28 EDTPCRXFollow-up: Pacira upgraded to Buy on valuation at BofA/Merrill
Subscribe for More Information
15:13 EDTPCRXPacira upgraded to Buy from Neutral at BofA/Merrill
Subscribe for More Information
January 27, 2016
07:30 EDTPCRXPiper reiterates Overweight on Pacira after surgeon survey
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use